Business
Recce Pharmaceuticals (ASX:RCE) share price tumbles despite positive update

Not even the release of a positive announcement has been able to stop the Recce Pharmaceuticals Ltd (ASX: RCE) share price from dropping today.
In afternoon trade, the biotechnology company’s shares are down 2.5% to 94 cents.
What did Recce announce?
This afternoon Recce Pharmaceuticals announced that the European Patent Office has granted patents relating to Recce 327 (R327) and Recce 529 (R529).
R327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria. This includes their superbug forms.
Whereas R529 is a new synthetic polymer formulation with indication against viruses. Recce is currently undertaking initial studies of R529 to indicate any potential therapeutic effect…
-
Business23 hours ago
Where will Berkshire Hathaway be in 1 year?
-
Noosa News18 hours ago
Two trapped and fighting for life after major three-vehicle crash in Brisbane
-
Business19 hours ago
Up 105% in a year, are Pro Medicus shares still a good buy today?
-
Business17 hours ago
Everything you need to know about the Coles dividend